Results 221 to 230 of about 41,188 (289)

A Dual-Feature Framework for Enhanced Diagnosis of Myeloproliferative Neoplasm Subtypes Using Artificial Intelligence. [PDF]

Bioengineering (Basel)
Bamaqa A, Labeeb NS, El-Gendy EM, Ibrahim HM, Farsi M, Balaha HM, Badawy M, Elhosseini MA.   +7 more
europepmc   +1 more source

MESENCHYMAL STEM CELLS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: IDLE OBSERVERS OR PART OF THE DISEASE? [PDF]

, 2019
Accurso, V., Cordova, A., Di Piazza, F., Di Stefano, A. B., Lo Re, J., Mancuso, S., Russo, A., Santoro, M., Siragusa, S.   +8 more
core   +1 more source

ZRSR2 loss causes aberrant splicing in JAK2^V617F-driven myeloproliferative neoplasm but is not sufficient to drive disease progression. [PDF]

Hemasphere
Zhang R, Straube J, Janardhanan Y, Haldar R, Cooper L, Hayes N, Laurore C, Kim CJ, Luskin MR, Lindsley RC, Stahl M, Mullally A, Marneth AE, Bywater M, Lane SW.   +14 more
europepmc   +1 more source

Formononetin acts synergistically with a JAK2 inhibitor to suppress growth in myeloproliferative neoplasm by inhibiting JAK/STAT3 signaling pathway

, 2023
Huijun Jiang, Zaijing Fan, Jiashan Li, Xiaoqun Zheng   +3 more
openalex   +2 more sources

Pathways to myeloproliferative neoplasm presentation and time to diagnosis: results from a cross-sectional study. [PDF]

BJGP Open
Tarburn EL, Iversen L, Robertson C, McShane C, Duncombe A, McMullin MF, Harrison C, Mesa R, Anderson LA.   +8 more
europepmc   +1 more source

A Case of Myeloproliferative Neoplasm with Eosinophilia Associated with PCM1-JAK2 Rearrangement. [PDF]

Case Rep Oncol
Zhou W, Guo X, Liu Y, Hao Z, Chu S, Zhang L, Li L.   +6 more
europepmc   +1 more source

JAK1 somatic mutation in a myeloproliferative neoplasm

Haematologica, 2017
Suzanne O. Arulogun, Hock-Lai Choong, Debbie Taylor, Paula Ambrosoli, Graham Magor, Ian M. Irving, Tee-Beng Keng, Andrew C. Perkins   +7 more
doaj   +1 more source

Autophagosome-lysosome mediated secretion of the thrombopoietin receptor is modulated by distinct driver mutations of myeloproliferative neoplasm. [PDF]

Leukemia
Chowdhury S, Shrivastva S, Singh A, Ansari F, Naseer S, Roy A.   +5 more
europepmc   +1 more source

Response: cancer risk in chronic myeloproliferative neoplasms [PDF]

, 2012
Henrik Frederiksen, Dóra Körmendiné Farkas, Christian Fynbo Christiansen, Hans Carl Hasselbalch, Henrik Toft Sørensen   +4 more
openalex   +1 more source

Case Report: Myelodysplastic/myeloproliferative neoplasm with concurrent SF3B1, ASXL1, JAK2 and CBL mutations and <15% bone marrow ringed sideroblasts. [PDF]

Front Oncol
Wang Y, Jin S.
europepmc   +1 more source